What is one serious side effect of extended-spectrum beta-lactamase (ESBL)-producing organisms?

The serious side effect of extended-spectrum beta-lactamase (ESBL)-producing organisms is primarily their resistance to many beta-lactams. ESBLs are enzymes produced by certain types of bacteria, primarily Escherichia coli and Klebsiella pneumoniae, that confer resistance to a wide range of beta-lactam antibiotics, which include penicillins and cephalosporins. As these organisms produce ESBLs, they can hydrolyze and inactivate these antibiotics, rendering them ineffective. This resistance complicates treatment options significantly, leading to challenges in managing infections caused by such organisms.

Infections caused by ESBL-producing bacteria often require the use of other classes of antibiotics, such as carbapenems, which may be more effective but are also associated with their own side effects and risks, including potential toxicity or resistance issues with prolonged use. This intensifies the need for careful antibiotic stewardship and the consideration of infection control measures in healthcare settings, as these resistant organisms can spread readily among patients.

While the other choices relate to important aspects of antibiotic pharmacology and infection management, they do not represent the primary concern associated with ESBL-producing organisms, which is their ability to resist treatment with many commonly used beta-l